<DOC>
	<DOCNO>NCT02038868</DOCNO>
	<brief_summary>The purpose study compare efficacy ASP4901 placebo patient benign prostatic hyperplasia . The safety tolerability ASP4901 also evaluate .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ASP4901 Patients With Benign Prostate Hyperplasia</brief_title>
	<detailed_description>This multicenter , randomize , parallel-group , placebo-controlled , active-referenced , double-blind study . After obtain write consent , patient meet eligibility criterion preliminary enrollment receive oral administration placebo single-blinded manner ( single-blind placebo run-in period ) . Then , patient meet eligibility criterion main enrollment receive drug placebo ( double-blind treatment period ) 4 week . Furthermore , patient follow 1 week confirm safety study drug treatment period ( safety follow-up period ) .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>dysuria associate BPH least 12 week provide consent total IPSS core 13 high QOL score 3 high maximum urinary flow rate ( Qmax ) ≥4 mL/sec &lt; 15 mL/sec . prostate volume ≥20 mL . A postvoid residual volume ( PVR ) &gt; 350 mL A previous concurrent symptomatic urinary tract infection within 4 week study A cataract operation schedule perform study period Previous concurrent clinically relevant cardiovascular cerebrovascular disorder within 24 week prior study Hypersensitivity ASP4901 tamsulosin hydrochloride Presence serious hepatic disease , renal disease , immunological disease , pulmonary disease clinically relevant</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>BPH</keyword>
	<keyword>ASP4901</keyword>
</DOC>